In the subsequent Vasodilator Heart Failure Trial II (V-HeFT II), the efficacy of the H/I combination was compared with enalapril, an angiotensin-converting enzyme inhibitor (ACE inhibitor). The gene discussed is ACE; the disease is heart failure.